Samuel Kaufman
Psychiatric/Mental Health · Riverside, RINPI 1306326202
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (59.5%), speaking fees and education — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by AbbVie at 51.8% of the total. Reporting peaked in 2022 at $6,946 and has fallen 73.2% since, to $1,865 in 2025. Among psychiatric/mental health clinicians in RI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 581 payments — averaging $33.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$10K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Lundbeck LLC$952
- Axsome Therapeutics, Inc.$878
- Supernus Pharmaceuticals, Inc.$820
- Otsuka America Pharmaceutical, Inc.$788
- plus $5K from 14 others
What the payments were for
- Speaking & faculty fees$7,70040%
- Food & beverage$11,58760%
- Education$1801%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 155 | $10,075 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 59 | $1,127 |
| Lundbeck LLC | 39 | $952 |
| Axsome Therapeutics, Inc. | 37 | $878 |
| Supernus Pharmaceuticals, Inc. | 18 | $820 |
| Otsuka America Pharmaceutical, Inc. | 41 | $788 |
| Johnson & Johnson | 30 | $734 |
| Neurocrine Biosciences, Inc. | 22 | $629 |
| Vanda Pharmaceuticals Inc. | 21 | $595 |
| Alkermes, Inc. | 29 | $544 |
| Takeda Pharmaceuticals U.S.A., Inc. | 30 | $474 |
| Ironshore Pharmaceuticals Inc. | 21 | $430 |
| Teva Pharmaceuticals USA, Inc. | 22 | $414 |
| Corium, LLC | 19 | $343 |
| Sunovion Pharmaceuticals Inc. | 14 | $246 |
| E.r. Squibb & Sons, L.L.C. | 10 | $162 |
| Idorsia Pharmaceuticals US Inc | 5 | $87 |
| Neos Therapeutics, LP | 4 | $82 |
| Bausch Health US, LLC | 3 | $47 |
| Almatica Pharma LLC | 2 | $41 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,467 in reported general payments places this provider in the 95th percentile of 196 psychiatric/mental health providers in Rhode Island.
See all psychiatric/mental health providers in Rhode Island →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 34 | $43,083 |
| VraylarCariprazine Hcl | 17 | $25,350 |
| VyvanseLisdexamfetamine Dimesylate | 12 | $4,313 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 32 | $722 |
| Duloxetine Hcl | 19 | $528 |
| Gabapentin | 13 | $341 |
| Lamotrigine | 18 | $208 |
| Clonazepam | 22 | $103 |
| Trazodone Hcl | 11 | $92 |
| Diazepam | 11 | $37 |
| Lorazepam | 13 | $33 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato | $734 | $43,08334 claims |
| AbbVieVraylar | $10,075 | $25,35017 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $474 | $4,31312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 196 psychiatric/mental health providers in Rhode Island.
Other psychiatric/mental health in Riverside
- Britni TuranoRiverside$5K
- Katelyn AgnewRiverside$3K
- Elizabeth RaposaRiverside$1K
- Samantha Shawn MarshBradford$639K
- Katie ThayerWarwick$16K
- Arielle RoundsWarwick$15K
- Eniayo EgberongbeCranston$12K
- Deborah HorvitzWarwick$10K
- Donna McDonaldProvidence$9K
- Timothy PepinNorth Smithfield$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.